We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Sorrento Therape (SRNE) is a leading biotechnology business with stocks listed in the US. It opened the day at US$2.01 after a previous close of US$2.01. During the day the price has varied from a low of USD2 to a high of USD2.2. The latest price was USD2.15 (25 minute delay). Sorrento Therape is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| Open | US$2.01 |
|---|---|
| High | US$2.2 |
| Low | US$2 |
| Close | US$2.15 |
| Previous close | US$2.01 |
| Change | US$0.14 |
| Change % | 6.9652% |
| Volume | 9,729,508 |
| 52-week range | US$1.15 - US$11.07 |
|---|---|
| 50-day moving average | US$1.646 |
| 200-day moving average | US$4.0832 |
| Target price | US$21 |
| PE ratio | N/A |
| Dividend yield | US$0 (0%) |
| Earnings per share (TTM) | US$-1.527 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $2.15
| 1 week (2022-06-23) | -5.70% |
|---|---|
| 1 month (2022-06-03) | 25.73% |
| 6 months (2021-12-31) | -53.76% |
| 1 year (2021-07-02) | -77.96% |
|---|---|
| 2 years (2020-07-02) | -68.61% |
| 3 years (2019-07-03) | -13.65% |
| 5 years (2017-07-03) | 13.16% |
| Revenue TTM | US$57 million |
|---|---|
| Gross profit TTM | US$-167,049,000 |
| Return on assets TTM | -32.96% |
| Return on equity TTM | -206.57% |
| Profit margin | 0% |
| Book value | 0.616 |
| Market capitalisation | US$805.1 million |
TTM: trailing 12 months
We're not expecting Sorrento Therape to pay a dividend over the next 12 months.
Sorrento Therape's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.
Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as US$1.15 up to US$11.07. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 2.4288. This would suggest that Sorrento Therape's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Everything we know about the Octava Minerals IPO, plus information on how to buy in.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
